LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Net Interest Income

Last Annual Value

3.92M

3-Year CAGR

57%

5-Year CAGR

31%

10-Year CAGR

15%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Net Interest Income

LBRX · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.92M
N/AN/AN/A 
6.63M
-8.3%N/AN/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
9.72M
0.8%N/AN/A
2.14M
-50.4%28.6%42.5%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
-8.66M
N/AN/AN/A
8.61M
60.1%N/AN/A
13.08M
-17.7%62.2%N/A
13.23M
31.3%N/AN/A
2.68M
-27.6%90.1%N/A
8.72M
-14.7%N/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
0.00
N/AN/AN/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95